Underuse of trimodality treatment affects survival for patients with inflammatory breast cancer: an analysis of treatment and survival trends from the National Cancer Database.
about
Conservative mastectomies for breast cancer and risk-reducing surgery: the Memorial Sloan Kettering Cancer Center experienceEffects of payer status on breast cancer survival: a retrospective study.Disulfiram (DSF) acts as a copper ionophore to induce copper-dependent oxidative stress and mediate anti-tumor efficacy in inflammatory breast cancer.Using the National Cancer Data Base for quality evaluation to assess adherence to treatment guidelines for nonmetastatic inflammatory breast cancer.Towards a transcriptome-based theranostic platform for unfavorable breast cancer phenotypes.Prognostic impact of hormone receptor- and HER2-defined subtypes in inflammatory breast cancer treated with high-dose chemotherapy: a retrospective study.Management of locally advanced breast cancer-perspectives and future directions.Immediate Reconstruction in Inflammatory Breast Cancer: Challenging Current Care.Inflammatory breast cancer: a proposed conceptual shift in the UICC-AJCC TNM staging system.The Impact of Residual Disease After Preoperative Systemic Therapy on Clinical Outcomes in Patients with Inflammatory Breast Cancer.Disparities in the Use of Postmastectomy Radiation Therapy for Inflammatory Breast Cancer.Inflammatory breast cancer in the Netherlands; improved survival over the last decades.Private Payer's Status Improves Male Breast Cancer Survival.Chemotherapy response and survival of inflammatory breast cancer by hormone receptor- and HER2-defined molecular subtypes approximation: an analysis from the National Cancer Database.Inflammatory Breast Cancer: Patterns of Failure and the Case for Aggressive Locoregional Management.The Impact of Subtype Distribution in Inflammatory Breast Cancer Outcome
P2860
Q26768204-114D3166-143B-49BD-A54C-756B5774016AQ35248415-AC347847-71D8-4EF3-85AF-79CC2270E00AQ35825566-7D1E0BD7-FF0D-412E-BC84-E2051A118639Q36308501-2B88AE28-201A-4E0B-A6EB-85912ADB317DQ37417906-BF719472-A77A-4A67-95E7-6E7D985B8D06Q37427956-5DE4B272-F350-48FC-9E6D-5029C080066CQ38350939-A0F6FF65-9B9A-447D-B02E-F32C72868336Q38957313-92D65AC1-BE7A-4656-B3C0-C3ED3361B7BCQ39214862-4EC8F802-9A83-46E3-B5E8-F2C91E0FC5C6Q39339815-562912D0-17E2-4EDE-8CAD-9C809982F4F9Q39746375-6C69A8E1-E2E6-4E10-82A7-9DE345052167Q40358255-E0CF3F75-50FE-4F7E-951D-362A7A529814Q40382440-8B880636-C1E6-4D77-8CAE-4CB9CCAD6013Q40553911-8EF789E4-399C-496E-93C6-6DA49D0758D5Q54283392-2C48DE0C-EA42-48C2-91BA-CDAD4C2CCEBAQ57054849-FE793A5F-BB13-42CF-94BB-E460855AC81C
P2860
Underuse of trimodality treatment affects survival for patients with inflammatory breast cancer: an analysis of treatment and survival trends from the National Cancer Database.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Underuse of trimodality treatm ...... the National Cancer Database.
@ast
Underuse of trimodality treatm ...... the National Cancer Database.
@en
type
label
Underuse of trimodality treatm ...... the National Cancer Database.
@ast
Underuse of trimodality treatm ...... the National Cancer Database.
@en
prefLabel
Underuse of trimodality treatm ...... the National Cancer Database.
@ast
Underuse of trimodality treatm ...... the National Cancer Database.
@en
P2093
P2860
P356
P1476
Underuse of trimodality treatm ...... the National Cancer Database.
@en
P2093
Gildy Babiera
Heather Y Lin
Isabelle Bedrosian
Naoto T Ueno
Natasha M Rueth
Simona F Shaitelman
P2860
P304
P356
10.1200/JCO.2014.55.1978
P407
P577
2014-06-02T00:00:00Z